Prescription weight loss medication may be an option for adults who meet a product’s eligibility criteria and have an appropriate medical assessment. A discussion with a physician should cover health goals, safety, medication choice, follow-up, and the full cost of care. Medication supports an eating, activity, and behavior plan rather than replacing it.
General adult eligibility often starts at a body mass index (BMI) of 30 or above, or 27 or above with a weight-related condition. These thresholds do not guarantee a prescription or establish that a particular product is suitable.
By Empire Medical Wellness Editorial Team
Published: 2026
Updated: 2026
Table of Contents
- Who Might Be Considered for Prescription Weight Loss Medication
- How Weight Loss Medication Classes Work in Plain Language
- Eligibility Review and Safety Screening Steps
- Comparing Medication Classes and Labeled Products
- Follow-Up, Maintenance, and Realistic Expectations
- Planning for Private-Pay Costs and Questions to Ask
- Frequently Asked Questions About Prescription Weight Loss Options
Who Might Be Considered for Prescription Weight Loss Medication
BMI is a screening measure calculated from height and weight. It does not directly measure body fat or describe a person’s overall health.
A clinician considers BMI alongside medical history, weight-related conditions, previous treatment, and other findings. Appearance alone cannot establish a diagnosis or determine whether prescription treatment is appropriate.
Common Starting Points and What They Do Not Mean
The following general adult thresholds come from NIDDK guidance. Product-specific eligibility and safety requirements still apply.
| General Starting Point | What It Does Not Mean |
|---|---|
| BMI of 30 or above | Not an automatic prescription; an individualized assessment is still needed |
| BMI of 27 or above with a weight-related condition | Not a guarantee that any particular product is suitable |
Weight-related conditions may include high blood pressure or type 2 diabetes. The clinician must check which conditions and eligibility requirements apply to the actual medication being considered.
These thresholds are general principles, not proof that Empire Medical Wellness prescribes automatically at a cutoff.
Using the NIDDK Overview and Current Labels
The National Institute of Diabetes and Digestive and Kidney Diseases explains general principles in its overview on prescription medications for overweight and obesity.
Its June 2024 product table should not be treated as a complete 2026 drug list. It remains useful background reading, but current FDA-approved labeling is needed for product-specific decisions.
Three principles help organize the discussion:
- Medication is used alongside nutrition, physical activity, and behavior support.
- Eligibility and suitability require an individual assessment.
- Each product has its own approved indications, formulations, warnings, and limitations.
An indication is the condition or purpose for which a product is approved. The same active ingredient can appear in products with different indications.
How Weight Loss Medication Classes Work in Plain Language
Prescription obesity medications work through different mechanisms. Some affect appetite and fullness signals. Others reduce the absorption of dietary fat.
The mechanism alone does not establish which option is appropriate. The exact product’s evidence, approved use, safety information, and practical requirements matter. NIDDK and the FDA-approved labels listed in the Sources section provide the basis for these distinctions.
Gut Hormones That Signal Fullness
GLP-1 stands for glucagon-like peptide-1, a hormone involved in appetite regulation and blood sugar control. GLP-1 receptor agonists act on this hormone’s receptor. Some also slow stomach emptying, with effects that depend on the product and treatment stage.
Wegovy contains semaglutide, while Saxenda contains liraglutide. Their formulations and prescribing requirements differ.
Zepbound contains tirzepatide, which acts on both GIP and GLP-1 receptors. GIP is another hormone involved in the body’s response to food. Zepbound’s labeled uses include adult weight management and treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. Its label specifies the populations and accompanying treatment measures.
Nerve-Acting and Fat-Blocking Options
Phentermine is a sympathomimetic medicine, meaning it has stimulant-like effects on the nervous system. Products such as Adipex-P and Lomaira are labeled for short-term use as an adjunct to weight-management measures.
Contrave combines naltrexone and bupropion and acts on pathways involved in appetite regulation. Qsymia combines phentermine and topiramate in an extended-release formulation.
Xenical contains orlistat. It reduces the activity of digestive enzymes called lipases, so some dietary fat is not absorbed. Each option has distinct contraindications, interactions, and monitoring needs.
A medication’s mechanism explains how it works. It does not establish that it is safer, more effective, or more suitable for every adult.
Reading Trial Results Carefully
A useful trial summary identifies the drug, study population, dose, formulation, duration, and comparator. It should also explain which analysis produced the reported result.
SURMOUNT-1 studied weekly injected tirzepatide at 5, 10, or 15 milligrams for 72 weeks in adults with obesity, or overweight with a weight-related complication, without diabetes. Participants also received lifestyle intervention.
The primary treatment-regimen analysis reported average weight changes of −15.0%, −19.5%, and −20.9%, respectively, compared with −3.1% with placebo. A separate efficacy analysis produced different estimates. The peer-reviewed trial report is linked in Sources.
The manufacturer’s announcement, SURMOUNT-1 results published in the New England Journal of Medicine, provides additional context but is not the independent medical evidence for these figures.
These are research doses and group averages, not dosing instructions, Empire outcomes, or predictions for an individual.
Labeled Uses Versus Off-Label Use
FDA-approved use follows the product’s approved labeling, including the relevant indication, formulation, and population.
Off-label use means prescribing outside an approved use. It is not automatically inappropriate, but it requires clinical judgment and a discussion of the evidence, uncertainties, and alternatives.
A diabetes product does not become an FDA-approved obesity product simply because it contains the same ingredient as one.
Eligibility Review and Safety Screening Steps
Safety screening helps establish whether a medication’s potential benefits justify its risks. It also identifies what needs monitoring if treatment is prescribed.
The following checklist is a discussion aid, not a complete screening tool. Current product labeling determines the specific requirements.
Core Topics a Clinician Typically Reviews
An assessment may include:
- Weight and treatment history: previous approaches, duration, benefits, and difficulties.
- Medical conditions: blood pressure, diabetes, cardiovascular disease, and kidney or liver problems.
- Digestive history: symptoms or conditions relevant to the medication being considered.
- Current medicines and supplements: prescription products, over-the-counter medicines, vitamins, and herbal products.
- Previous medication responses: side effects, allergies, and reasons treatment ended.
- Pregnancy and family planning: pregnancy, breastfeeding, and plans to conceive.
- Personal and family history: including medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 when relevant.
- Product-specific concerns: such as seizure history, glaucoma, or interactions with other medicines.
This information supports safer selection. It does not guarantee that medication will be prescribed.
Why Product Labels Come First
A boxed warning is the most prominent warning in U.S. prescribing information. Wegovy and certain other products have boxed warnings concerning thyroid C-cell tumors observed in rodents. Whether these findings translate into the same risk in humans is unknown.
For Wegovy, a personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2, is a contraindication.
A contraindication is a circumstance in which a medicine should not be used. Contraindications differ by product; one class-wide checklist is not enough.
Other warnings, precautions, interactions, and monitoring requirements also matter. The current label—not a general comparison article—governs those details.
Setting Goals Beyond the Scale
Goals should reflect the person’s health priorities and the outcomes that treatment can reasonably address.
Possible measures to discuss include blood pressure, blood sugar, mobility, physical function, and weight-related symptoms. Not every medication is approved to improve every outcome, and improvement is not guaranteed.
A hypothetical functional goal might be walking a familiar route with fewer rest stops. Recording the starting point makes later discussion more specific.
How Clinicians Weigh Benefit Against Risk
Selection involves potential benefit, contraindications, side effects, coexisting conditions, route, affordability, and patient preferences.
A new pregnancy plan, a significant medical event, or a medication interaction may change the options. Sometimes the appropriate decision is further evaluation or a nonmedication approach.
No supplied data establish which medication class Empire starts most often. There is also no single preferred drug for every adult.
Sharing Information With Other Clinicians
Ask how relevant information can be shared with other treating clinicians and what consent is needed. Privacy rules permit some information-sharing for treatment without a separate authorization, so it is better to clarify the practice’s process than assume every disclosure requires permission.
For related preparation, see what a first obesity medicine appointment involves.
Bring an accurate medication list and questions about any unclear history. These details can help prevent avoidable gaps in the assessment.
Comparing Medication Classes and Labeled Products
Products in the same class can differ in approved uses, formulations, strengths, and safety requirements. The exact product matters more than the ingredient name alone.
Why Class Names Can Mislead
“GLP-1” identifies a mechanism, not a complete prescription. Likewise, “semaglutide” does not identify whether a product is a tablet or injection, what it is approved to treat, or which dose applies.
Similar names should not be treated as evidence that products can be substituted.
Reading the Labeled Product Table
The following is a 2026 discussion framework, not a complete drug list or treatment ranking. It summarizes selected products; current labels remain the authority.
The table deliberately omits dose schedules. It should not be used to select a starting dose, convert between formulations, or change treatment.
Medication Classes and Labeled Examples
| Class or Mechanism | Example Labeled Products | Key Selection Considerations |
|---|---|---|
| GLP-1 receptor agonist | Wegovy: semaglutide tablets and injection; Saxenda: liraglutide injection | Exact formulation and indication, thyroid warning, digestive effects, other label precautions |
| GIP and GLP-1 receptor agonist | Zepbound: tirzepatide injection | Weight-management or sleep-apnea indication, contraindications, digestive effects, cost |
| Sympathomimetic amine | Adipex-P and Lomaira: oral phentermine products | Short-term indication, cardiovascular contraindications, interactions |
| Phentermine with topiramate | Qsymia: oral extended-release capsules | Pregnancy risk, glaucoma, relevant interactions, monitoring requirements |
| Naltrexone with bupropion | Contrave: oral extended-release tablets | Seizure risk, uncontrolled hypertension, opioid-related contraindications, interactions |
| Lipase inhibitor | Xenical: oral orlistat capsules | Malabsorption-related contraindications, digestive effects, vitamin absorption, interactions |
These summaries come from the FDA-approved labeling resources listed in Sources. They do not reproduce every warning or identify an Empire formulary.
Factors a Clinician Weighs
Shared selection considers several questions together:
- Does the product’s approved indication fit the treatment goal?
- Are there contraindications or important interactions?
- Which adverse effects and monitoring requirements matter?
- Is the formulation practical for the person’s routine?
- Can the person reasonably sustain the total cost?
A potentially effective option may still be unsuitable because of safety, practical requirements, or affordability.
Semaglutide Is Not Always an Injection
The current Wegovy prescribing information includes tablets as well as injection. The applicable indication, population, strengths, and dosing requirements must be checked for the specific formulation.
Wegovy tablets and injection should not be assumed to have identical labeling or interchangeable doses.
Ozempic is another semaglutide product with its own diabetes-related labeling. Its ingredient does not make it interchangeable with Wegovy or establish an approved obesity indication.
Same Ingredient, Different Labels
Mounjaro and Zepbound both contain tirzepatide, but their approved uses differ. Mounjaro has type 2 diabetes labeling; Zepbound has weight-management and obstructive-sleep-apnea indications for specified adult populations.
Matching ingredients do not establish matching indications, doses, or substitution instructions.
This article provides no personal dosing guidance. A clinician must use the current label for the actual product and formulation.
The NIDDK overview on prescription medications explains general selection principles.
A related discussion addresses how GLP-1 and phentermine options compare.
Follow-Up, Maintenance, and Realistic Expectations
Obesity can require long-term management. NIDDK explains that medication may be continued when it is beneficial and tolerated, and that weight may return after treatment ends.
A short course should not be presented as a permanent cure. Follow-up helps determine whether the current approach remains appropriate.
What Follow-Up Visits Review
Follow-up generally addresses four questions:
- Is treatment providing meaningful benefit?
- Are side effects or safety concerns emerging?
- Is the plan practical to follow?
- Should treatment continue, change, or end under clinical supervision?
The schedule depends on the medication, clinical situation, and monitoring requirements. No fixed Empire follow-up interval is assumed here.
A Simple Monitoring Checklist
Topics to review may include:
- Weight trend: interpreted over time rather than from a single reading.
- Appetite and eating: changes in hunger, fullness, intake, and meal tolerance.
- Symptoms: including digestive symptoms or other new concerns.
- Function: mobility and activities selected as treatment goals.
- Relevant measurements: such as blood pressure or blood sugar when appropriate.
- Laboratory testing: based on clinical need and product requirements.
- Practical barriers: missed treatment, access problems, or unaffordable costs.
Ask which symptoms warrant prompt contact and how to reach the treating clinician. A general checklist cannot replace product-specific safety instructions.
Why Weight Can Return After Stopping
Weight-management medicines do not permanently remove the biological influences on appetite and weight. NIDDK notes that some weight regain is likely after stopping medication.
The STEP 1 trial illustrates treatment efficacy, not what happens after stopping. In that 68-week trial, adults with obesity, or overweight with a weight-related condition, without diabetes received weekly injected semaglutide 2.4 milligrams or placebo, alongside lifestyle intervention.
Average weight change was −14.9% with semaglutide and −2.4% with placebo. These are study results, not a promised outcome or instructions to use that dose.
The formulation, population, duration, and comparator are described in the STEP 1 weight reduction findings.
Measuring Progress Beyond the Scale
No verified Empire six-month outcomes dataset was supplied, so this guide reports no practice average.
A progress worksheet can instead document baseline measures, changes, side effects, and questions. It helps distinguish benefit from tolerability and practical barriers.
A useful record includes what is improving, what is difficult, and what needs reassessment—not only weight.
Planning Ahead for Maintenance
Maintenance discussions can cover sustainable eating and activity patterns, continued support, medication access, and follow-up if treatment changes.
For related background, see how maintenance planning works after medication.
Changes to medication belong in a clinical discussion. This guide does not advise readers to start, stop, or adjust treatment.
Planning for Private-Pay Costs and Questions to Ask
Empire Medical Wellness provides private-pay, physician-led outpatient care. Medication and laboratory costs are separate from care fees.
A useful estimate includes the full treatment period under consideration, not just the initial appointment.
Understanding Private-Pay Visit Fees
Ask the practice for current evaluation and follow-up fees before scheduling. No verified fee schedule, visit duration, reimbursement policy, or package information is supplied here.
Also ask what the quoted care fee includes and which services may generate separate charges.
Medication and laboratory costs are separate. A consultation fee should not be assumed to include either.
Estimating Total Cost Over Time
Use a written estimate with these categories:
- Initial evaluation fees.
- Expected follow-up fees.
- The exact medication, formulation, and pharmacy price.
- Clinically indicated laboratory testing.
- Any other disclosed care-related charges.
Ask whether prices may change and whether a proposed estimate assumes insurance coverage, a discount program, or cash payment.
Coverage and reimbursement are not guaranteed. Confirm medication benefits with the insurer and actual dispensing costs with the pharmacy rather than relying on a general price estimate.
Where Visits Take Place
Confirm current appointment formats, locations, and eligibility directly with the practice. For telemedicine, ask whether care is available where the patient will physically be during the appointment.
No service states, in-person locations, appointment availability, or response times are assumed in this guide.
For related cost questions, see our guide to GLP-1 online without insurance.
Questions to Ask Before Starting
Use this neutral worksheet during a consultation. It supports discussion without assuming that a prescription will be offered.
| Discussion Topic | Question to Ask | Notes |
|---|---|---|
| Eligibility | Which findings support consideration of medication, and what needs further assessment? | |
| Goals | Which health measures and daily activities will be tracked? | |
| Safety | Which contraindications, warnings, or interactions are relevant? | |
| Product choice | What are the exact product, formulation, approved indication, and alternatives? | |
| Labeled use | Is the proposed use FDA-approved or off-label? What evidence supports it? | |
| Tolerability | Which symptoms require prompt contact, and what is the contact process? | |
| Follow-up | What will be monitored, and how will benefit be reassessed? | |
| Total cost | What are the separate care, medication, and laboratory costs? | |
| Maintenance | What is the plan if treatment becomes ineffective, unsuitable, or unaffordable? |
Tracking Progress Between Visits
Use measures agreed on with the clinician. The worksheet is a record for discussion, not a tool for making independent medication changes.
| Date | Health markers or functional goals | Symptoms and tolerability | Access or cost concerns | Questions for next visit |
|---|---|---|---|---|
Short, consistent notes can make a follow-up more useful than a detailed record that is difficult to maintain.
Next Steps and Important Notes
Current practice information is available on the Empire Medical Wellness website.
Before scheduling, clarify the evaluation process, appointment requirements, and separate costs. An appointment is an opportunity for assessment, not a guaranteed prescription.
Frequently Asked Questions About Prescription Weight Loss Options
These questions address practical details that may remain after an initial review.
Does a BMI Number Alone Decide Eligibility?
No. The general thresholds identify when discussion may be appropriate, but product-specific requirements and individual safety screening still apply.
Previous treatment, medical conditions, medications, pregnancy plans, and goals can affect the decision. Meeting a threshold does not establish suitability.
What Is the Difference Between FDA-Approved and Off-Label Use?
FDA-approved use is covered by the product’s approved labeling. Off-label use falls outside that labeling, which can involve a different indication, population, dose, or route.
Ask what evidence supports the proposed use and what uncertainties remain. Off-label prescribing does not mean the FDA has approved that particular use.
Are Compounded Products the Same as FDA-Approved Products?
No. Compounded drugs are not FDA-approved. FDA does not review them for safety, effectiveness, and quality before marketing in the same way it reviews approved products.
The FDA’s information on unapproved GLP-1 drugs explains relevant concerns. This article does not recommend compounded medication or imply that Empire offers it.
Related terminology is discussed in our guide to compounded semaglutide and its labeling questions.
How Long Does Treatment Last?
Duration depends on the product, response, safety, and ongoing assessment. Some products are labeled for short-term use; others support long-term management.
There is no universal stopping date. Discuss continuation criteria, affordability, and maintenance before making any medication change.
Sources
The following sources support general eligibility principles, product-specific labeling, and the research summaries. Historical trial dates do not establish current product availability.
- NIDDK Overview on Prescription Medications for Overweight and Obesity
- FDA-Approved Labeling for Named Products, via Drugs@FDA
- Wegovy (semaglutide) Prescribing Information
- SURMOUNT-1 Trial Report, New England Journal of Medicine
- STEP 1 Trial Report, New England Journal of Medicine
To learn more about private-pay, physician-led outpatient care, explore our obesity medicine services.
This article is educational and is not personal medical advice. It does not diagnose a condition or instruct anyone to start, stop, or change medication.